Table 1.
Characteristics of the Study Populationa
| Characteristic | Study Participants, No. (Column %)b | P Value | ||
|---|---|---|---|---|
| Total (n = 320) | <AIN2 (n = 232) |
AIN2+ (n = 88) |
||
| Age, mean (SD), y | 52.8 (9.1) | 53.1 (9.4) | 51.8 (8.3) | .30 |
| Race | ||||
| White | 267 (83.4) | 190 (81.9) | 77 (87.5) | .23 |
| Nonwhite | 41 (12.8) | 32 (13.8) | 9 (10.2) | .39 |
| Data missing | 12 (3.8) | 10 (4.3) | 2 (2.3) | … |
| Ethnicity | ||||
| Non-Hispanic | 227 (70.9) | 165 (71.1) | 62 (70.5) | .91 |
| Hispanic | 29 (9.1) | 24 (10.3) | 5 (5.7) | .19 |
| Data missing | 64 (20.0) | 43 (18.5) | 21 (23.9) | … |
| HPV statusc | ||||
| Positive | 259 (80.9) | 171 (73.7) | 88 (100.0) | <.001d |
| Negative | 59 (18.4) | 59 (25.4) | 0 (0.0) | |
| Data missing | 2 (0.6) | 2 (0.9) | 0 (0.0) | … |
| HPV genotypee | ||||
| HPV-16/18f | 119 (45.9) | 61 (35.7) | 58 (65.9) | <.001d |
| HPV-16 positiveg | 97 (37.5) | 45 (26.3) | 52 (59.1) | <.001d |
| HPV-18 positive, HPV-16 negativeh | 22 (8.5) | 16 (9.4) | 6 (6.8) | .49 |
| Other HR-HPVi | 140 (54.1) | 110 (64.3) | 30 (34.1) | <.001d |
| HIV viral load | ||||
| <75 Copies/mL | 277 (86.6) | 201 (86.6) | 76 (86.4) | .95 |
| ≥75 Copies/mL | 31 (9.7) | 25 (10.8) | 6 (6.8) | .29 |
| Data missing | 12 (3.8) | 6 (2.6) | 6 (6.8) | … |
| CD4 cell count | ||||
| ≥350/µL | 252 (78.8) | 190 (81.9) | 62 (70.5) | .03d |
| <350/µL | 56 (17.5) | 36 (15.5) | 20 (22.7) | .13 |
| Data missing | 12 (3.8) | 6 (2.6) | 6 (6.8) | … |
| Any prior anal cancer screening | ||||
| Yes | 160 (50.0) | 114 (49.1) | 46 (52.3) | .62 |
| No | 15 (4.7) | 13 (5.6) | 2 (2.3) | |
| Data missing | 145 (45.3) | 105 (45.3) | 40 (45.5) | … |
| Ever smoker | ||||
| Yes | 149 (46.6) | 100 (43.1) | 49 (55.7) | .04d |
| No | 119 (37.2) | 98 (42.2) | 21 (23.9) | |
| Data missing | 52 (16.3) | 34 (14.7) | 18 (20.5) | … |
| Lifetime no. of male partners | ||||
| 0–4 | 46 (14.4) | 38 (16.4) | 8 (9.1) | .10 |
| 5–39 | 112 (35.0) | 88 (37.9) | 24 (27.3) | .07 |
| ≥40 | 101 (31.6) | 66 (28.4) | 35 (39.8) | .05 |
| Data missing | 61 (19.1) | 40 (17.2) | 21 (23.9) | … |
Abbreviations: AIN, anal intraepithelial neoplasia; <AIN2, AIN less than grade 2 by cytology and histology; AIN2+, AIN grade 2 or 3 by cytology and/or histology; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR-HPV, high-risk human papillomavirus; SD, standard deviation.
Univariate analyses of study population demographics and risk factors dichotomized by case status. All information was collected from a self-administered questionnaire completed by study participants or extracted from electronic medical records, and χ2 tests were used to identify statistically significant differences (P < .05) between participants with <AIN2 and those with AIN2+.
Data represent no. (column %) except where identified as mean (SD).
Defined as positive for HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68; otherwise considered negative.
Significant at P < .05 for comparison between <AIN2 and AIN2+ groups.
HPV genotypes for participants with positive HPV results; percentages represent proportion of those with positive results.
Positive for HPV-16 or HPV-18, regardless of other positive HPV results.
Positive for HPV-16, regardless of other positive HPV results.
Positive for HPV-18 but negative for HPV-16.
Negative for HPV-16 or HPV-18 but positive for any of the other 12 high-risk HPV types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68.